VivoSeq
Other

Vaginitis

13

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Vaginitis is an emerging landscape with 13 programs across 7 companies. The most active players are Toltec Pharmaceuticals, LLC, GSK, Johnson & Johnson. 2 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

86/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Toltec Pharmaceuticals, LLC

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 3A

AVVA Pharmaceuticals Ltd.

2 programs

Phase 3S

Solvay Pharmaceuticals

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

12

clinical trials

Completed6 · 50%
Recruiting2 · 17%
Unknown status2 · 17%
Not yet recruiting1 · 8%
Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository
Recruiting·PPeking University Shenzhen Hospital·Phase 3·NCT04574089·50 enrolled
Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis
Recruiting·AAVVA Pharmaceuticals Ltd.·Phase 2/3·NCT06835361·264 enrolled
Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream
Not yet recruiting·FFujian Cancer Hospital·Phase 4·NCT07492654·238 enrolled
A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT01867164·160 enrolled
TOL-463 Phase 2 Study for Vaginitis
Completed·TToltec Pharmaceuticals, LLC·Phase 2·NCT02866227·106 enrolled
Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis
Completed·LLaboratoire Innotech International·Phase 4·NCT02444481·169 enrolled
Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis
Completed·LLaboratoire Innotech International·Phase 3·NCT02515656·661 enrolled
Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.
Completed·—·Phase 2/3·NCT03005353·100 enrolled
Effects of LiveSpo X-SECRET in SupportiveTreatment of Vaginitis
Completed·AAnabio R&D·N/A·NCT06165354·120 enrolled
Efficacy Vulvovaginitis Candida
Terminated·JJ. Uriach and Company·Phase 2·NCT00199264·60 enrolled
Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis
Unknown status·—·Phase 1·NCT00479947·100 enrolled
Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis
Unknown status·UUniversità degli Studi dell'Insubria·Phase 2/3·NCT01420510·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)